2025 International Congress » Parkinson's disease: Biomarkers (non-Neuroimaging)

Meeting: 2025 International Congress

1H-NMR and UPLC/MS Metabolomics Identify Disrupted Homeostasis of Energy, Amino Acids, and Glutathione Metabolism as Serum Signatures in Parkinson’s Disease Patients

A. Imarisio, J. Gervasoni, C. Marino, L. Santucci, E. Napolitano, T. Nuzzo, I. Yahyavi, M. Avenali, M. Cicchinelli, C. Galandra, M. Picascia, M. Grimaldi, C. Pacchetti, F. Errico, AM. D'Ursi, A. Urbani, A. Usiello, EM. Valente (Rome, Italy)

A Prospective, Observational Study to Identify Biomarkers in Parkinsonian Syndromes (proATYP).

M. Makrygianni, D. Potamianou, T. Pipikos, M. Xilouri, C. Mourmouris, A. Sarafi, L. Florentin, M. Stamelou (Athens, Greece)

Advancing the regulatory maturity of digital health technologies with focus on early intervention, Critical Path for Parkinson’s 3DT initiative

D. Stephenson, C. Coon, J. Cosman, M. Dockendorf, S. Dolan, J. Edgerton, L. Gaetano, E. Goikoetxea, D. Hill, G. Jones, S. Jorgensen, T. Kangarloo, C. Kopil, G. Lee, J. Mammen, A. Mirelman, C. Ollivier, K. Romero, S. Sardar, Y. Xiao, M. Müller, J. Adams (Tucson, USA)

Alpha-Synuclein Amplification Assays Utilizing Real-Time Quaking-Induced Conversion (RT-QuIC) from Non-Invasive Saliva as a Novel Diagnostic Tool for Patients with Parkinson’s Disease

PRA. Sharma, RK. Dhamija (Delhi, India)

Alpha-Synuclein Preformed Fibrils Increase the Frequency of CXCR3+ B-cells in Early-stage Parkinson’s Disease Patients

H. Hong, M. Dean, D. Standaert, H. Qin, E. Benveniste (Birmingham, USA)

Amplification Parameters of the Alpha-Synuclein Seed Amplification Assay on CSF Predict the Clinical Subtype of Parkinson’s Disease at 10-Year Follow-Up

P. Grillo, GM. Riboldi, A. Pisani, UJ. Kang, SM. Fereshtehnejad (Pavia, Italy)

Analyzing Longitudinal Correlation Between CSF Tau, Alpha-Synuclein, and Dysautonomia in Parkinson’s Disease Over Five Years

C. Song, J. Ruiz Tejeda, R. Rajmohan, N. Phielipp (Irvine, USA)

AntiSaccadeNet: A Deep Learning Framework for Differentiating Parkinsonian Disorders through Antisaccade Time Series Classification

S. Patel, C. Antoniades, J. Fitzgerald, O. Bredemeyer (Oxford, United Kingdom)

Association of periodontal pathogen with subtypes of motor symptoms of Parkinson’s disease

H. Yamada, M. Nakamori, H. Nishi, H. Naito, Y. Yamazaki, H. Maruyama (Hiroshima, Japan)

Associations among blood biomarkers, clinical subtypes, and prognosis in Parkinson’s disease

H. Oizumi, T. Hasegawa, I. Kawahata, T. Totsune, Y. Sugimura, T. Baba, H. Tanaka, T. Takahashi, M. Yoshioka, T. Sekimori, K. Fukunaga, A. Takeda (Sendai, Japan)

Balance biomarker for early differentiation of Parkinson’s disease and multiple system atrophy with parkinsonian type

HJ. Chang, JH. Kim, S. Lee, E. Kwon, SH. Jeong, E. Oh (Daejeon, Republic of Korea)

Basal Ganglia Physiomarkers of Non-motor Symptoms in Parkinson’s Disease: a Systematic Review

B. Keulen, M. Beudel, A. Malekzadeh, R. de Bie, B. Swinnen (Amsterdam, Netherlands)

Biomarker Panels for Parkinson’s Disease using Multi-Omics Approach: Recent Developments and Future Directions

PRA. Sharma, RK. Dhamija (Delhi, India)

Blood and CSF Biomarkers of Cognitive Impairment in Alpha Synucleinopathies

C. Girges, N. Vijiaratnam, N. O’Reilly, J. Hay, V. Chelban, D. Athauda, H. Morris, H. Houlden, S. Gandhi, T. Foltynie (London, United Kingdom)

Blood levels of Cathepsin B are linked to a reduced risk of Parkinson’s disease

X. Guo, R. Li (Xi'an, China)

Blood-based biomarkers for diagnosis and prediction of Parkinson’s Disease in GBA1 individuals

M. Avenali, L. Bandirali, S. Caminiti, P. Mitrotti, L. Gallo, R. Stiuso, R. Calabrese, G. Cuconato, C. Galandra, C. Tassorelli, S. Cerri, EM. Valente, F. Blandini (Pavia, Italy)

Broad spectrum local field potential activities as a novel biomarker for adaptive deep brain stimulation

CH. Tai, YC. Lin, WH. Hu, MT. Hsu, SH. Tseng (Hsinchu, Taiwan)

Can Wearable Inertial Sensors Accurately Reflect Parkinson’s Disease Severity? A Systematic Review and Meta-Analysis

H. Youssef, M. Sabıroğlu, S. Abdelrahman, T. Hasanin, M. Manay, M. Gönül, S. Del Din, A. Vural (Istanbul, Turkey)

Characterization of DBS-induced Speech Improvements in a German PD Cohort

G. Brandt, K. Simon, T. Dembek, M. Barbe, T. Thies (Cologne, Germany)

Characterization of neuronal exosomes purified from plasma of Parkinson’s Disease Chilean patients

V. Urbina, C. Aguilera, E. Larraechea, D. Sepulveda, R. Vidal (Santiago, Chile)

Chronic DBS Stimulation’s effects after 1-hour off stimulation

M. Varga, Y. Zhao, S. Santacruz (Austin, USA)

Chronic Exercise and Systemic Inflammation in Parkinson’s Disease: Exploring the Role of Exercise Modality

J. Cristini, F. Seo, A. Bon, A. Potvin-Desrochers, J. Mustafa, A. Dagher, R. Postuma, P. Rosa-Neto, J. Carrier, A. Amara, S. Steib, C. Paquette, M. Roig (Montreal, Canada)

Classification of Medication State in Parkinson’s Disease Patients with and without Fluctuations using Facial Videos

I. Boura, V. Skaramagkas, G. Karamanis, I. Kyprakis, D. Fotiadis, Z. Kefalopoulou, M. Tsiknakis, C. Spanaki (Heraklion, Crete, Greece)

Clinical Characteristics of Sporadic Parkinson’s Disease with Negative CSF Alpha-synuclein Seed Amplification Assay

S. Brooker, J. Pasquini, S. Choi, D. Lafontant, K. Marek, T. Simuni, P. Gonzalez-Latapi, N. Pavese, K. Poston (Chicago, USA)

Cognitive and Motor Wobbling in Isolated RBD: A Multicentric Study by the International RBD Study Group (IRBDSG)

A. Stefani, S. Joza, D. Arnaldi, L. Baldelli, G. Benbir, B. Boeve, V. de Cock, L. Churchill, B. Högl, M. Hu, B. Huang, R. Kim, K. Kufer, J-Y. Lee, C. Liguori, B. Mollenhauer, L. Muntean, N. Li, B. Orso, M. Patyjewicz, R. Postuma, F. Provini, S. Lewis, C. Simonet, M. Sommerauer, A. Videnovic, Y. Wing, C. Trenkwalder (Innsbruck, Austria)

Color Vision In Patients With Clinical Manifestations Of Rem Sleep Behavior Disorder

F. Tressino, G. Pereira, N. Bruscato, C. Rieder, A. Schuh (Porto Alegre, Brazil)

Comprehensive Multi-Platform Proteomic Analysis Identifies Novel Biomarkers for Parkinson’s Disease Diagnosis and Progression Monitoring

D. Brazel, E. Boyle, L. Gattermeyer-Kell, M. Martinez-Serrat, C. Tafrali, W. Hu, L. Voloboueva, S. Tiwari, A. Hari, F. Qureshi, M. Khalil, P. Schwingenschuh (Menlo Park, USA)

CSF Cadaverine and Other Polyamines as Biomarkers of Parkinson’s Disease: A PPMI Metabolomics Analysis

N. Xia, R. Maciuca, J. Suh, J. Kluss, S. Davis, R. Bakshi, G. Crotty, A. Ascherio, E. Macklin, S. Huntwork-Rodriguez, M. Schwarzschild (Charlestown, USA)

CSF Mitochondrial DNA Indicates Body Composition and Energy Metabolism in Parkinson’s Disease.

Y. Mizutani, T. Nakai, Y. Maeda, R. Ohdake, R. Nagao, S. Shima, K. Kawabata, A. Ueda, M. Ito, H. Watanabe (Toyoake, Japan)

Daily Activity Analysis of Parkinson’s Disease Using Machine Learning with 3D Poses

KD. Kim, S. Lyu, T. Dunn (Durham, USA)

Detection of α-synuclein Seeds in Skin and CSF Samples from PPMI Participants.

L. Concha-Marambio, Y. Ma, C. Farris, R. Johnson, S. Rosete-Gonzalez, D. Murphy, K. Merchant, S. Hutten, T. Simuni, T. Tropea, M. Frasier, J. Hamer, K. Marek, T. Foroud (San Diego, USA)

Diagnostic accuracy and clinical correlates of real-time quaking-induced conversion assay on gastric biopsy in early Parkinson’s disease

C. Shin, JP. Im, JY. Han, B. Jin, KA. Woo, S. Lee, HY. Jeon, JY. Joo, HJ. Chang, JH. Shin, HJ. Kim, JM. Kim, YP. Choi, B. Jeon (Seoul, Republic of Korea)

Digital measurement of ocular microtremor in Parkinson’s Disease: Analytical and clinical validation

L. Graham, R. Vitorio, P. Tait, R. Walker, A. Godfrey, R. Morris, S. Stuart (Newcastle-upon-Tyne, United Kingdom)

Distinct Peripheral Immune Profiles of Parkinson’s Disease and Multiple System Atrophy

S. Jo, I. Jang, J. Lee, M. Choi, E. Lee, SJ. Chung (Seoul, Republic of Korea)

Dopa Decarboxylase as a Biomarker for Parkinsons Disease and Its Relationship to L-Dopa Influence and Sample Size Estimates

J. Chung, A. Rhodes, P. Artoni, Y. Matsuki, K. Otake, J. Padmanabhan, D. Prilutsky (Cambridge, USA)

Dopamine replacement therapy modulates dopa decarboxylase, prolactin and AOC3 levels in Parkinson’s disease

L. van Hillegondsberg, S. Ahmad, M. Fletcher, A. Taylor, A. Thompson, M. Hu (Oxford, United Kingdom)

Dried Plasma Spot Cards for Measurement of Neurofilament Light Chain

B. Huxford, P. Gklinos, F. Rios, N. Vickaryous, L. Schalk, A. Noyce, R. Dobson (London, United Kingdom)

Enhancing Parkinson’s Disease Detection Through Chemical and Motor Biomarkers

C. Marshall, M. Kling, L. Linch, N. Hashemi, E. Stegemoller (Ames, USA)

Enhancing Step Detection in Real-World Gait

A. Ena, C. Mazzà, E. Bartholomé, C. Bernasconi, S. Belachew, ó. Reyes (Basel, Switzerland)

Epigenome-wide and gene-targeted epigenetic profile of isolated REM Sleep Behaviour Disorder: a clinico-molecular study

L. Baldelli, C. Pirazzini, L. Sambati, F. Ravaioli, F. Di Laudo, D. Gentilini, P. Guaraldi, C. Franceschi, P. Cortelli, P. Garagnani, G. Calandra-Buonaura, MG. Bacalini, F. Provini (Bologna, Italy)

Evaluation of the Pharmacodynamic Effects of BIIB122/DNL151 in Participants with LRRK2 mutation-driven Parkinson’s disease (BEACON Study)

J. Kluss, S. Huntwork-Rodriguez, D. Jennings, S. Ota, R. Maciuca, J. Alkabsh, S. Davis, J. Suh, M. Schwarzschild, K. Fraser, R. Llorens-Arenas, C. Ho, P. Chin (South San Francisco, USA)

Eye movement abnormalities in GBA1-related Parkinson’s disease and non-manifesting GBA1-carriers

G. Riboldi, T. Hudson, H. Conn, K. Astudillo, J. Rizzo, S. Frucht, J. Rucker (New York, USA)

Eye tracking identifies biomarkers predicting Parkinson’s disease before motor symptom onset

A. Yoritaka, M. Ando, S. Nakayama, K. Fusegi, S. Nojiri, A. Tozuka, Y. Wang, W. Urasaki, N. Hattori (Saitama, Japan)

Facial Blendshape Index(FBI) for Quantification of Hypomimia on Parkinson´s Disease

B. Koyak, T. Menzel, M. Botsch, A. Spottke, M. Reuter, U. Wüllner, NA. Aziz (Dortmund, Germany)

Glossography – a novel, computer-vision based technique for assessing and treating involuntary tongue movements in dyskinetic episodes in Parkinson’s disease

M. Brzezicki, M. Palczynski, E. Pilchowska-Ujma, O. Szymańska-Adamcewicz, N. Pawlak, P. Lesniak, S. Jurga (Oxford, United Kingdom)

Identification of Metabolomic & Proteomic Panels for Parkinson’s Disease progression Diagnosis

A. Galal, A. Moustafa, M. Salama (Cairo, Egypt)

Identification of Rigidity in Parkinson’s Disease Using Wearable Technology

P. Sharma, C. Sotirakis, J. Huxley, J. Fitzgerald, C. Antoniades (Oxford, United Kingdom)

Individual physiomarkers of levodopa-induced local field potential fluctuations interact with deep brain stimulation in Parkinson’s disease

M. de Neeling, C. Oehrn, B. Keulen, M. Stam, D. Hubers, R. de Bie, P. Schuurman, B. van Wijk, A. Buijink, M. Beudel (Sacramento, USA)

Interpretable voice-based detection of Parkinson’s disease using language-independent graph neural networks

S. Patel, C. Antoniades, J. Fitzgerald, O. Bredemeyer (Oxford, United Kingdom)

iPad App-based Eye Tracking for the Early Detection of Parkinson’s Disease

F. David, J. Koerner, E. Zou, J. Karl, C. Poon, C. Sodini, V. Sze, L. Verhagen-Metman, T. Heldt (Chicago, USA)

Isolation of Seeding Competent Material by Means of ThT Extraction

C. Farris, Y. Ma, D. Murphy, S. Rosete-Gonzalez, L. Concha (san diego, USA)

L1CAM and TMEM119 enriched Exosomal markers in Parkinson’s Disease and Progressive Supranuclear Palsy: A Prospective Study

A. Roy, S. Brahmachari, A. Pantelyat, L. Rosenthal, V. Dawson, T. Dawson (Gaithersburg, USA)

Long-term analysis of subthalamic local field potentials (LFP) in Parkinson’s disease: Insights into circadian rhythms, medication, and personalized treatment effects

V. Livneh, R. Naivelt, M. Zutta, Z. Katzir, R. Monteoriano, I. Strauss, K. Avirame, A. Socher, G. Morris, I. Maidan (Tel Aviv, Israel)

Low-frequency pallidum evoked potential dynamics as a prospective biomarker for Parkinson’s disease

B. Mohanty, N. Perera, K. O'Neill Iii, S. Alberico, M. Hill, D. Bauer, B. Pobiel, J. Froula, D. Darrow, M. Park, J. Wang, L. Johnson, J. Aman, J. Vitek (Minneapolis, USA)

Lysosomal Lipid Dysregulation in Parkinson’s Disease: Genetic and Medication Effects in CSF Metabolomics

J. Suh, R. Maciuca, E. Macklin, S. Davis, J. Kluss, N. Xia, H. Yazd, M. Schwarzschild, S. Huntwork-Rodriguez (South San Francisco, USA)

Mapping aggregate monopolar sensing data of beta power local field potentials onto a common subthalamic nucleus in Parkinson’s disease patients

M. Case, C. Zarns, A. Holt-Becker, R. Raike, E. Radcliffe, A. Baumgartner, J. Thompson, D. Kern (Minneapolis, USA)

Metabolomic breath landscape analysis unravels lipid biomarker candidates in patients with monogenic and idiopathic Parkinson’s disease

M. Malik, N. Brüggemann, T. Usnich, M. Borsche, T. Demetrowitsch, K. Schwarz, P. Bauer, K. Lohmann, C. Klein, T. Kunze (Luebeck, Germany)

Metabolomics Profiling in Egyptian Patients with Alzheimer’s and Parkinson’s Diseases

S. Abdelaziz, A. Helmy, E. Hamid, M. Salama, A. Shalash (Cairo, Egypt)

Modifiers of Parkinson’s disease associated with mutations in the GBA1 gene based on transcriptome data validation

A. Bezrukova, K. Basharova, I. Miliukhina, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

Monitoring Parkinson’s Disease in the Dental Chair

J. Schwartz, L. Dibenedetto, P. Engen, V. Ha, B. Killinger, C. Soto, S. Green, A. Naqvi, S. Tomar, M. Shaikh, M. Villanueva, D. Sanchez-Bass, C. Noh, R. Voigt, C. Goetz, A. Keshavarzian (Chicago, USA)

Multiplex Proteomic Analysis of Lewy Body Dementia Reveals Cerebrospinal Fluid Biomarkers of Disease Pathophysiology and Progression

L. Higginbotham, A. Shantaraman, Q. Guo, E. Fox, P. Bagchi, F. Wu, J. Lah, A. Levey, N. Seyfried (Altanta, USA)

Neural Network Models Predict Parkinson’s Disease Using Brief-Action Motion Sensor Data

S. Panchawagh, Z. Zibly, V. Santini (Pune, India)

Neutrophil Extracellular Traps Reveal Novel Inflammatory Signatures in Parkinson’s Disease and Multiple System Atrophy

C. Ying, M. Zhang, H. Zhang, Y. Li, W. Mao, Y. Cai (Beijing, China)

Novel Insights into the Association Between Parkinson’s Disease and Constipation: Role of SHMT2 as a Promising Biomarker

JH. Su, EX. Tao (Shenzhen, China)

Novel Usage of Alpha Synuclein as a Biomarker for Screening Parkinson’s disease at Komfo Anokye Teaching Hospital in Ghana

YAW. Osei, SF. Sarfo, FAY. Yeboah Agyemang (Kumasi, Ghana)

Paradoxical Association of Kinetics of α-Synuclein Seed Amplification 24-hrs Assay and Clinico-Pathological Markers of Parkinson’s disease

SM. Fereshtehnejad, Y. Zeighami, C. Marras (TORONTO, Canada)

Parkinson’s Disease and Type 2 Diabetes Severity: a Case-control Biomarker Study

B. Huxford, A. Zirra, E. Camboe, K. Dey, D. Gallagher, C. Budu, C. Simonet, T. Boyle, R. Dobson, A. Noyce (London, United Kingdom)

Parkinson’s disease Symptoms Mitigated by Photobiomodulation: The Potential of the Tryptophan Kynurenine Ratio as a Marker for Responsiveness to Therapy.

A. Liebert, B. Bicknell (Wahroonga, Australia)

Phase 1 and 1b Pharmacodynamic Data Support Central Modulation of Lysosomal Pathways With BIIB122/DNL151, a LRRK2 Kinase Inhibitor: Insights for the LUMA Trial

K. Fraser, A. Lang, L. Kalia, R. Hauser, J. Greenamyre, Y. Moroishi, J. Kluss, B. Hersh, K. Ferber, R. Maciuca, C. Paián-Ruiz, R. Llorens-Arenas, D. Jennings, S. Huntswork-Rodriguez, D. Graham (Tampa, USA)

Phosphorylated High Mobility Group Box Protein 2 (HMGB2) as a Potential Biomarker for Parkinson’s Disease

J. Fan, J. Liu, C. Mesaros, I. Blair (Philadelphia, USA)

Plasma Biomarkers Predict Clinical Outcomes in Individuals with Neuronal α-Synuclein Disease and Amyloid-β Co-Pathology

S. Lorkiewicz, C. Abdelnour, A. Smith, N. Siddiqui, L. Montoliu-Gaya, E. Wilson, N. Ashton, B. Arslan, M. Plastini, C. Young, J. Winer, M. Shahid-Besanti, H. Vossler, V. Ramirez, G. Kerchner, K. Andreasson, V. Henderson, T. Montine, L. Tian, E. Mormino, H. Zetterberg, K. Poston (Gothenburg, Sweden)

Plasma Lipids as Potential Biomarkers for Progression of Sleep Disturbances in Parkinson’s Disease

M. Mchorney, R. Rajhmohan, J. Ruiz Tejeda, N. Phielipp (Irvine, USA)

Plasma neurofilament light chain in early Parkinson’ s disease predicts motor complications: A Prospective Cohort Study

NN. Che (Chengdu, Sichuan, China)

Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease

T. Tropea, P. Aldea Stevenson, M. Flitter, D. Meehan, A. Morris, M. Lu, L. Iaccarino, E. Collins, M. Hodsdon, L. Shaw, E. Lee, D. Weintraub, A. Chen-Plotkin, M. Mintun, A. Siderowf (Philadelphia, USA)

Plasma Protein Profiles Reveal Distinct Molecular Signatures in Parkinson’s Disease and Multiple System Atrophy

SJ. Chung, S. Jo, I. Jang, J. Lee, M. Choi, E. Lee (Seoul, Republic of Korea)

Plasma proteomic proﬁles and risk of Parkinson’s disease: a prospective study from UK Biobank

C. Li, B. Ke, X. Zheng, Y. Xiao, S. Wang, Q. Jiang, J. Lin, J. Huang, H. Shang (Chengdu, China)

Platelets Lipidome as Potential Biomarker of Parkinson’s Disease

G. Uras, S. Lucas-Del-Pozo, V. Lentini, F. Fierli, S. Koletsi, D. Hughes, A. Schapira, . (London, United Kingdom)

Predicting Parkinson’s disease severity and cognitive decline using blood-based ferroptotic biomarkers

V. Huin, E. Cailliau, G. Garçon, M. Dutheil, O. Simonin, N. Beauval, J. Labreuche, D. Blum, C. Moreau, E. Hainque, A. Marques, A. Eusebio, I. Benatru, C. Brefel-Courbon, D. Maltete, C. Giordana, M. Tir, S. Thobois, JP. Brandel, B. Jarraya, L. Hopes, O. Rascol, JC. Corvol, D. Devos, AS. Rolland (Lille, France)

Privacy and Personalisation: Predicting Parkinson’s Severity with Federated Learning

C. Hinchliffe, H. Hiden, E. Packer, P. Brown, A. Yarnell, L. Rochester, L. Alcock, M. Peeters, S. Del Din, P. Watson (Newcastle upon Tyne, United Kingdom)

Quantitative Digitography and Home Diaries for PD Motor State Evaluation

K. Daley, A. Negi, S. Karjagi, A. Abay, P. Acharyya, P. Schmiedmayer, K. Wilkins, H. Bronte-Stewart (Palo Alto, USA)

Quantitative Measures of Cutaneous Phosphorylated Alpha-Synuclein: Powering a Disease Modification Clinical Trial In Parkinson’s Disease

C. Gibbons, B. Bellaire, H. Khona, T. Levine, R. Freeman, B. Li, M. Dey, B. Henderson (Boston, USA)

Real world application of alpha-synuclein skin biopsy in the diagnosis of synucleinopathies at a tertiary care center

C. Yu, C. Cooper (Nashville, USA)

Reduced plasma levels of small HDL subfractions in advanced Parkinson’s disease

CM. Chen, KH. Chang, ML. Cheng (Taoyuan, Taiwan)

Relationship Between Motor Subtypes and Central and Peripheral Neurodegeneration in Early Parkinson’s Disease: A Study Using DAT SPECT and SUDOSCAN

T. Shimizu, S. Moriyasu, K. Taneda, N. Tokuda, Y. Ugawa, R. Hanajima (Tokyo, Japan)

Saccadic mask-induced inhibition in Parkinson’s disease

P. Daye, T. de Araujo, H. Ciupe, A. Ramirez-Zamora, C. de Hemptinne, P. Pouget (Ottignies-Louvain-la-Neuve, Belgium)

Salivary Biomarkers in Parkinson’s Disease: A Follow-Up Study

MI. de Bartolo, D. Belvisi, E. Patricolo, M. Costanzo, C. Cutrona, F. Aiello, G. Leodori, A. Conte, G. Fabbrini, A. Berardelli, G. Vivacqua (Rome, Italy)

Serum based estimations of CFAH, Gelsolin, CNDP1 and DKK3 levels suggest involvement of multiple pathways in pathogenesis of Parkinson’s disease.

P. Alladi, S. Choudhury, H. Jyothi, R. Bhavani, V. Holla, A. Mahadevan, N. Kamble, P. Pal, R. YADAV. (Bengaluru, India)

Sex Differences in α-Synuclein Seed Amplification Assay Parameters and Longitudinal Clinical Subtypes of Parkinson’s Disease

SM. Fereshtehnejad, J. Lökk (TORONTO, Canada)

Single- and Multi-Unit Activity in STN Provides Enhanced Insight into Speech-Related Neural Dynamics in Parkinson’s Patients

Z. Jourahmad, A. Rohl, J. Greenlee (Iowa City, USA)

Sleep-wake Alterations are Associated with a Decreased DTI-ALPS, a Marker of Perivascular Glymphatic Functioning, in Patients with Isolated REM Sleep Behavior Disorder

I. Roura, J. Pardo, C. Martín-Barceló, C. Falcon, R. Sala-Llonch, C. Garcia-Vicente, N. Bargalló, M. Serradell, C. Gaig, G. Mayà, A. Montini, J. Madrir, M. Rol, A. Adan, C. Junqué, A. Iranzo, B. Segura (Barcelona, Spain)

Sleep-wake modulation of subthalamic activity in patients with Parkinson’s disease and conventional or adaptive deep brain stimulation

L. Caffi, R. Habib, S. Bonvegna, M. Pilleri, G. Pezzoli, C. Palmisano, A. Mazzoni, IU. Isaias (Milan, Italy)

Staging Disease Progression from Prodromal to Overt Stage of Alpha-synucleinopathies

D. Arnaldi, M. Roascio, E. Antelmi, F. Biscarini, L. Baldelli, V. Brunetti, E. Capriglia, E. Casaglia, A. Castelnuovo, G. Della Marca, L. Ferini-Strambi, R. Ferri, M. Figorilli, A. Galbiati, B. Guarnieri, D. Hoxhaj, F. Di Laudo, C. Liguori, S. Marelli, P. Mattioli, M. Mulas, B. Orso, M. Pardini, F. Pizza, F. Placidi, G. Plazzi, F. Provini, L. Sambati, M. Puligheddu, G. Arnulfo (Genova, Italy)

Stratification study of alpha-synucleinopathy by body fluid biomarkers

R. Kamo, A. Okuzumi, M. Iseki, T. Hatano, N. Hattori (Tokyo, Japan)

Synchronized High Frequency Neural Oscillations as a Biomarker for Differentiating the Internal from the External Segment of the Globus Pallidus in Parkinson’s Disease

J. Aman, K. O'Neill, S. Safo, M. Hill, S. Alberico, R. Cole, L. Johnson, J. Wang, K. Domingo, L. de Almeida, S. Cooper, D. Darrow, R. Mcgovern Iii, M. Park, L. Eberly, J. Vitek (Minneapolis, USA)

The East London Parkinson Disease Project: Higher Immune Activation found in Patients with Parkinson’s Disease Dementia from a Diverse Population

A. Zirra, KC. Dey, E. Camboe, E. Bhadra, B. Huxford, R. Laban, N. Donkor, F. Nice, S. Valle Thomas, A. Gaspariunas, L. Mitchell, DA. Gallagher, C. Budu, C. Simonet, T. Boyle, AJ. Lees, D. Yadin, J. Dias, O. Cavlan, CR. Marshall, MT. Perinan, AJ. Noyce (London, United Kingdom)

The Impact of Anodal transcranial Direct Current Stimulation on the Metabolomic Profiles of Cerebrospinal Fluid in Parkinson’s Disease

KW. Park, WY. Jang, KS. Jang, MR. Choi (Gangneung-si, Republic of Korea)

The Moroccan LRRK2 Registry: Building Resources to Investigate the Penetrance and Phenotype of LRRK2 in North Africans

Y. Razouqi, M. Megraoui, F. Belahsen, L. Bouguenouch, B. Elmakhzen, H. Ouhabi, J. Aasfara, Y. Zaid, A. Atpu, L. Khalki, M. Rizig (Casablanca, Morocco)

The sphingolipid Lyso-Gb3, a biomarker for the lysosomal storage disorder Fabry Disease, is significantly elevated in blood from patients with Parkinson’s Disease

C. Beetz, C. Cozma, M. Iurascu, S. Fischer, S. Oppermann, K. Kandaswamy, P. Bauer (Rostock, Germany)